Sinusoidal obstruction syndrome natural history, complications and prognosis
|
Sinusoidal obstruction syndrome Microchapters |
|
Differentiating Sinusoidal obstruction syndrome from Other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Sinusoidal obstruction syndrome natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Sinusoidal obstruction syndrome natural history, complications and prognosis |
|
FDA on Sinusoidal obstruction syndrome natural history, complications and prognosis |
|
CDC on Sinusoidal obstruction syndrome natural history, complications and prognosis |
|
Sinusoidal obstruction syndrome natural history, complications and prognosis in the news |
|
Blogs on Sinusoidal obstruction syndrome natural history, complications and prognosis |
|
Directions to Hospitals Treating Sinusoidal obstruction syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
If left untreated, the severe form of sinusoidal obstruction syndrome is characterized by high mortality and progression to multiorgan failure
Natural History
- Sinusoidal obstruction syndrome is a common complication in patients with hematopoietic stem cell transplant.
- If left untreated, the severe form of sinusoidal obstruction syndrome is characterized by high mortality and progression to multiorgan failure.[1]
Complications
- Complications that can develop as a result of sinusoidal obstruction syndrome are:[2][3][4][5]
Prognosis
- Sinusoidal obstruction syndrome is considered mild, moderate or severe based on the clinical course during the first three months of hematopoietic cell transplantation.[6]
- Patients with a mild or moderate form of sinusoidal obstruction syndrome requires no specific therapy and can be managed with supportive care alone and generally has a good prognosis.[7]
- Patients with the severe sinusoidal obstruction syndrome has a high rate of mortality and can progress to multiorgan failure.[8]
Morbidity and mortality is associated with following factors:[9][10][11][12]
- Younger age in children
- Older age in adults
- Poor performance status
- Pre-existing hepatic dysfunction
- History of pancreatitis
- Advanced malignancy
- Acute leukemia
- Presence of acute graft-versus-host disease
- Allogeneic HCT
- Unrelated donor HCT
- Mismatched donor
- Prior abdominal irradiation
- High dose cytoreductive therapy
- Total body irradiation
References
- ↑ Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A; et al. (2010). "Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome". Biol Blood Marrow Transplant. 16 (2): 157–68. doi:10.1016/j.bbmt.2009.08.024. PMC 3018714. PMID 19766729.
- ↑ Grus T, Lambert L, Grusová G, Banerjee R, Burgetová A (2017). "Budd-Chiari Syndrome". Prague Med Rep. 118 (2–3): 69–80. doi:10.14712/23362936.2017.6. PMID 28922103.
- ↑ Lin M, Zhang F, Wang Y, Zhang B, Zhang W, Zou X, Zhang M, Zhuge Y (2017). "Liver cirrhosis caused by chronic Budd-Chiari syndrome". Medicine (Baltimore). 96 (34): e7425. doi:10.1097/MD.0000000000007425. PMC 5571988. PMID 28834866.
- ↑ Lane ER, Hsu EK, Murray KF (2015). "Management of ascites in children". Expert Rev Gastroenterol Hepatol. 9 (10): 1281–92. doi:10.1586/17474124.2015.1083419. PMID 26325252.
- ↑ Johnson DB, Savani BN (2012). "How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation?". Exp Hematol. 40 (7): 513–7. doi:10.1016/j.exphem.2012.04.004. PMID 22542577.
- ↑ McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA (1993). "Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients". Ann. Intern. Med. 118 (4): 255–67. PMID 8420443.
- ↑ Fan CQ, Crawford JM (2014). "Sinusoidal obstruction syndrome (hepatic veno-occlusive disease)". J Clin Exp Hepatol. 4 (4): 332–46. doi:10.1016/j.jceh.2014.10.002. PMC 4298625. PMID 25755580.
- ↑ Lopes JA, Jorge S (2011). "Acute kidney injury following HCT: incidence, risk factors and outcome". Bone Marrow Transplant. 46 (11): 1399–408. doi:10.1038/bmt.2011.46. PMID 21383682.
- ↑ Tabbara IA, Ghazal CD, Ghazal HH (1996). "Early drop in protein C and antithrombin III is a predictor for the development of venoocclusive disease in patients undergoing hematopoietic stem cell transplantation". J Hematother. 5 (1): 79–84. doi:10.1089/scd.1.1996.5.79. PMID 8646485.
- ↑ Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W, Hiller E (1997). "Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation". Blood. 89 (6): 2184–8. PMID 9058743.
- ↑ Faioni EM, Krachmalnicoff A, Bearman SI, Federici AB, Decarli A, Gianni AM, McDonald GB, Mannucci PM (1993). "Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver". Blood. 81 (12): 3458–62. PMID 8507881.
- ↑ Scrobohaci ML, Drouet L, Monem-Mansi A, Devergie A, Baudin B, D'Agay MF, Gluckman E (1991). "Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers". Thromb. Res. 63 (5): 509–19. PMID 1755004.